Trump Administration Extends Medicare Coverage for Weight Loss Drugs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
Source: seekingalpha
- Medicare Coverage Extension: The Trump administration has extended the short-term Medicare coverage for weight loss drugs until the end of 2027, responding to concerns from major health insurers about the long-term payment model, ensuring continued access to weight loss medications for patients.
- Direct Payment Mechanism: The new plan will have Medicare directly pay for weight loss medications instead of incorporating them into Medicare plans, alleviating the financial burden on health insurers and potentially increasing patient access and usage of these drugs, thus driving market growth.
- Data Collection Support: CMS indicated that this extension will facilitate data collection to support a more effective implementation of the long-term model, particularly in light of insufficient participation from health insurers, ensuring the feasibility and effectiveness of the policy.
- Insurer Participation Issues: CVS Health and UnitedHealth have expressed concerns regarding the long-term GLP-1 coverage model, with CVS explicitly opting out and UnitedHealth questioning its structure, highlighting the significance and complexity of insurer involvement in Medicare reforms.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.020
Low
950.00
Averages
1192
High
1500
Current: 903.020
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Rapid Growth of Hybrid Vehicle Market in India
- Surge in Hybrid Sales: According to a report by Care Ratings, hybrid vehicle sales in India reached 362,866 units in the financial year ending March 2026, up nearly fourfold from 98,010 units in 2020, indicating a strong consumer demand for better fuel efficiency, with hybrids expected to account for 10% of total car sales by FY2027.
- Limited EV Market Share: Despite the rising demand for electric vehicles, only 131,865 units are projected to be sold by March 2026, reflecting a consumer preference for hybrids due to concerns over inadequate charging infrastructure.
- Market Leaders: Toyota and Maruti Suzuki dominate the hybrid vehicle market in India, with Toyota selling 366,896 cars including 91,536 strong hybrids in FY2026, while Maruti sold 20,466 strong hybrids, further solidifying their market positions.
- Future Model Launches: Experts predict that more hybrid models will be launched in the next 12 months than in the past five years combined, driven by increasing consumer acceptance of hybrids that require no change in refueling habits, thereby propelling market growth.
See More
Eli Lilly Stock Valuation Analysis
- Psychological Price Barrier: Eli Lilly's current share price of $903 is perceived as a psychological barrier; while many investors focus on absolute prices, true valuation should consider the earnings generated per dollar invested, indicating that the stock may be reasonably valued.
- Diversified Pipeline Advantage: Lilly's revenue and earnings outlook are heavily influenced by the rapid adoption of its dual GIP/GLP-1 agonists, Mounjaro and Zepbound, while its anti-amyloid antibody, Kisunla, and dermatology and immunology programs further diversify its portfolio, reducing the risk associated with reliance on a single product.
- Forward Earnings Multiple Discount: Despite the expansion of Lilly's product portfolio, its current forward P/E ratio remains significantly lower than the euphoric peaks of the initial GLP-1 hype cycle, suggesting that investors are paying less for expected future earnings compared to a few years ago, reflecting a lack of market recognition for its diversified business.
- Long-Term Investment Opportunity: As new drugs transition from clinical promise to billion-dollar commercial realities, Lilly's earnings base is set to expand, leading to a potential re-rating of its valuation multiples, making the current price of $925 an attractive entry point for long-term investors.
See More
EU Regulatory Review of New Weight-Loss Pills to Conclude Soon
- Review Progress Update: Emer Cooke, head of the European Medicines Agency, announced at the Reuters Pharma Europe 2026 event in Barcelona that the regulatory review of a new generation of weight-loss pills will conclude this summer, providing a positive signal for the market and potentially accelerating the launch of related drugs.
- Increased Market Competition: Denmark's Novo Nordisk and U.S. rival Eli Lilly have recently launched weight-loss pills in the U.S., and the progress of the EU review will directly impact their competitive positions in the European market, especially against the backdrop of growing demand for weight-loss solutions.
- Optimistic Industry Outlook: With the regulatory review of new weight-loss pills nearing completion, it is expected to drive more innovative drugs to market, thereby meeting consumer demand for effective weight-loss solutions and further promoting growth in the pharmaceutical industry.
- Far-reaching Policy Impact: The swift advancement of this review not only reflects the EU's efficiency in drug approvals but may also set higher standards for future drug approvals, influencing the regulatory environment across the entire pharmaceutical sector.
See More
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Rapid Growth of Hybrid Vehicle Market in India
- Surge in Hybrid Sales: According to a report by Care Ratings, hybrid vehicle sales in India reached 362,866 units in the financial year ending March 2026, up nearly fourfold from 98,010 units in 2020, indicating a strong consumer demand for better fuel efficiency, with hybrids expected to account for 10% of total car sales by FY2027.
- Limited EV Market Share: Despite the rising demand for electric vehicles, only 131,865 units are projected to be sold by March 2026, reflecting a consumer preference for hybrids due to concerns over inadequate charging infrastructure.
- Market Leaders: Toyota and Maruti Suzuki dominate the hybrid vehicle market in India, with Toyota selling 366,896 cars including 91,536 strong hybrids in FY2026, while Maruti sold 20,466 strong hybrids, further solidifying their market positions.
- Future Model Launches: Experts predict that more hybrid models will be launched in the next 12 months than in the past five years combined, driven by increasing consumer acceptance of hybrids that require no change in refueling habits, thereby propelling market growth.
See More
Eli Lilly Stock Valuation Analysis
- Psychological Price Barrier: Eli Lilly's current share price of $903 is perceived as a psychological barrier; while many investors focus on absolute prices, true valuation should consider the earnings generated per dollar invested, indicating that the stock may be reasonably valued.
- Diversified Pipeline Advantage: Lilly's revenue and earnings outlook are heavily influenced by the rapid adoption of its dual GIP/GLP-1 agonists, Mounjaro and Zepbound, while its anti-amyloid antibody, Kisunla, and dermatology and immunology programs further diversify its portfolio, reducing the risk associated with reliance on a single product.
- Forward Earnings Multiple Discount: Despite the expansion of Lilly's product portfolio, its current forward P/E ratio remains significantly lower than the euphoric peaks of the initial GLP-1 hype cycle, suggesting that investors are paying less for expected future earnings compared to a few years ago, reflecting a lack of market recognition for its diversified business.
- Long-Term Investment Opportunity: As new drugs transition from clinical promise to billion-dollar commercial realities, Lilly's earnings base is set to expand, leading to a potential re-rating of its valuation multiples, making the current price of $925 an attractive entry point for long-term investors.
See More
EU Regulatory Review of New Weight-Loss Pills to Conclude Soon
- Review Progress Update: Emer Cooke, head of the European Medicines Agency, announced at the Reuters Pharma Europe 2026 event in Barcelona that the regulatory review of a new generation of weight-loss pills will conclude this summer, providing a positive signal for the market and potentially accelerating the launch of related drugs.
- Increased Market Competition: Denmark's Novo Nordisk and U.S. rival Eli Lilly have recently launched weight-loss pills in the U.S., and the progress of the EU review will directly impact their competitive positions in the European market, especially against the backdrop of growing demand for weight-loss solutions.
- Optimistic Industry Outlook: With the regulatory review of new weight-loss pills nearing completion, it is expected to drive more innovative drugs to market, thereby meeting consumer demand for effective weight-loss solutions and further promoting growth in the pharmaceutical industry.
- Far-reaching Policy Impact: The swift advancement of this review not only reflects the EU's efficiency in drug approvals but may also set higher standards for future drug approvals, influencing the regulatory environment across the entire pharmaceutical sector.
See More
